Study guide
10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications
APMLE Part I Basic Sciences Podiatry
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Lower Extremity Osteology
1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics
2 Chapter 2: Lower Extremity Arthrology & Ligaments
2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics
3 Chapter 3: Lower Extremity Myology & Compartments
3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations
4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy
4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces
5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods
5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines
6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology
6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods
7 Chapter 7: General & Cellular Pathology
7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors
8 Chapter 8: Systemic & Podiatric Pathology
8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation
9 Chapter 9: Organ-System Pathology
9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology
10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology
10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology
11 Chapter 11: Antimicrobial & Podiatric Therapeutics
11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology
12 Chapter 12: Systemic Pharmacology
12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents
13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy
13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways
14 Chapter 14: Histology, Integument, Embryology & Genetics
14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging
15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology
15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics
16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood
16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology
17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling
17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction
18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition
18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals
10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications
Key Takeaways Explain This Topic AI
Catecholamine synthesis begins with L-tyrosine and proceeds via rate-limiting tyrosine hydroxylase to DOPA, dopamine, norepinephrine, and epinephrine; synaptic transmission is terminated primarily by presynaptic NET reuptake.
Adrenergic receptors govern distinct physiological responses: alpha-1 (Gq) mediates vascular smooth muscle vasoconstriction and mydriasis; alpha-2 (Gi) mediates presynaptic negative feedback inhibition of NE release; beta-1 (Gs) increases cardiac rate, contractility, and renin secretion; beta-2 (Gs) drives bronchodilation, vasodilation, and glycogenolysis.
Epinephrine exhibits dose-dependent receptor affinity: low doses favor beta-2 vasodilation, whereas high doses drive alpha-1 vasoconstriction; when co-administered with local anesthetics in podiatry, it prolongs blockade duration and provides surgical hemostasis, but requires caution in compromised digital circulation.
Alpha-blockers include non-selective irreversible agents (phenoxybenzamine, used preoperatively in pheochromocytoma) and selective alpha-1 blockers (prazosin, doxazosin, associated with first-dose orthostatic syncope; tamsulosin, selective for alpha-1A in prostatic tissue).
Beta-blockers are classified into non-selective (propranolol), cardioselective beta-1 (metoprolol, atenolol), and combined alpha/beta antagonists (carvedilol, labetalol); major adverse consequences include bronchospasm in asthma, masking of hypoglycemia symptoms in diabetes, peripheral vasospasm in PAD, and severe bradycardia reversed by intravenous glucagon.
Last updated: October 2026
10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications
Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.
Catecholamine Biosynthesis, Storage, Release & Termination
Adrenergic transmission is mediated by endogenous catecholamines: Dopamine, Norepinephrine (Noradrenaline), and Epinephrine (Adrenaline) . Understanding their biochemical pathway is essential for interpreting sympathomimetic and sympatholytic pharmacology.
Biosynthetic Pathway
L-Tyrosine → \rightarrow → L-DOPA: L-Tyrosine is transported into adrenergic nerve terminals and hydroxylated to L-Dihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme Tyrosine Hydroxylase (TH) . This step requires molecular oxygen and tetrahydrobiopterin ( B H 4 BH_4 B H 4 ) and represents the absolute rate-limiting step in catecholamine synthesis.
L-DOPA → \rightarrow → Dopamine: L-DOPA is rapidly decarboxylated to Dopamine by DOPA Decarboxylase (Aromatic L-amino acid decarboxylase) , utilizing pyridoxal phosphate (Vitamin B 6 B_6 B 6 ) as a cofactor.
Dopamine → \rightarrow → Norepinephrine: Dopamine is transported into synaptic storage vesicles by the Vesicular Monoamine Transporter (VMAT-2) . Inside the vesicle, Dopamine β \beta β -Hydroxylase (DBH) hydroxylates dopamine to Norepinephrine (NE). This step requires Vitamin C (ascorbate) and copper.
Norepinephrine → \rightarrow → Epinephrine: In the adrenal medulla (and certain central adrenergic neurons), norepinephrine exits the vesicle and is methylated to Epinephrine by Phenylethanolamine N-Methyltransferase (PNMT) in the cytosol, utilizing S-adenosylmethionine (SAM) as a methyl donor. Synthesis of PNMT is heavily upregulated by cortisol delivered directly via intra-adrenal portal blood flow from the adrenal cortex. Catecholamine Synthesis
- L-Tyrosine
- │
- ▼ [Tyrosine Hydroxylase] (Rate-Limiting Step; BH4 dependent)
- L-DOPA
- │
- ▼ [DOPA Decarboxylase] (Vitamin B6 dependent)
- Dopamine
- │
- ▼ [Dopamine β-Hydroxylase] (Inside Storage Vesicle; Ascorbate dependent)
- Norepinephrine
- │
- ▼ [PNMT] (Adrenal Medulla only; Upregulated by Cortisol)
- Epinephrine
- Storage, Release & Termination of Transmission
Vesicular Storage & Reserpine: Catecholamines are concentrated inside vesicles via VMAT-2. The antihypertensive alkaloid Reserpine irreversibly inhibits VMAT-2, leaving cytosolic catecholamines unprotected against enzymatic degradation, thereby depleting presynaptic stores.
Exocytosis: Presynaptic depolarization opens N-type voltage-gated calcium channels; calcium influx triggers SNARE-mediated vesicular fusion and exocytosis of NE and ATP into the synaptic cleft.
Presynaptic Reuptake (NET / Uptake-1): In sharp contrast to acetylcholine, approximately 80 % − 90 % 80\% - 90\% 80% − 90% of synaptic norepinephrine is terminated by active presynaptic reuptake via the sodium-dependent Norepinephrine Transporter (NET-1) . Drugs that block NET—notably Cocaine and Tricyclic Antidepressants (TCAs) —prevent catecholamine clearance, intensely potentiating sympathetic actions.
Enzymatic Degradation (MAO & COMT): Un-recycled catecholamines are degraded by two principal enzymes:
Monoamine Oxidase (MAO): Located on the outer mitochondrial membrane of neurons and liver. MAO-A degrades NE, epinephrine, and serotonin ( 5 -HT 5\text{-HT} 5 -HT ); MAO-B selectively degrades dopamine.
Catechol-O-Methyltransferase (COMT): Located in the cytoplasm of post-synaptic tissues and liver; transfers a methyl group from SAM.
End-Stage Metabolite: The final common hepatic and renal breakdown product of norepinephrine and epinephrine is Vanillylmandelic Acid (VMA) , along with intermediate metanephrines and normetanephrines . Measurement of 24-hour urinary metanephrines and VMA serves as the premier diagnostic test for pheochromocytoma .
Adrenergic Receptor Taxonomy & Second Messenger Cascades
All adrenergic receptors are seven-transmembrane G-protein-coupled receptors (GPCRs). They are categorized into Alpha ( α 1 , α 2 \alpha_1, \alpha_2 α 1 , α 2 ) and Beta ( β 1 , β 2 , β 3 \beta_1, \beta_2, \beta_3 β 1 , β 2 , β 3 ) classes.
Receptor Subtype Primary G-Protein Downstream Biochemical Cascade Anatomical Distribution Classic Board-Tested Actions
α 1 \alpha_1 α 1 G q G_q G q Activates Phospholipase C (PLC) → ↑ I P 3 , D A G → ↑ intracellular C a 2 + \rightarrow \uparrow IP_3, DAG \rightarrow \uparrow \text{intracellular } Ca^{2+} →↑ I P 3 , D A G →↑ intracellular C a 2 + , PKC activation Vascular smooth muscle (skin, viscera, renal), pupillary dilator muscle, bladder neck/internal sphincter, prostate Vasoconstriction (increased SVR and BP); mydriasis (pupillary dilation); urinary sphincter contraction (urinary retention)
α 2 \alpha_2 α 2 G i G_i G i Inhibits adenylyl cyclase → ↓ c A M P \rightarrow \downarrow cAMP →↓ c A MP ; closes presynaptic C a 2 + Ca^{2+} C a 2 + channels Presynaptic adrenergic/cholinergic nerve terminals, pancreatic β \beta β -cells, platelets Presynaptic auto-inhibition (decreases NE release); central sympatholysis; decreased insulin release; platelet aggregation
β 1 \beta_1 β 1 G s G_s G s Stimulates adenylyl cyclase → ↑ c A M P → PKA activation → ↑ L-type C a 2 + influx \rightarrow \uparrow cAMP \rightarrow \text{PKA activation} \rightarrow \uparrow \text{L-type } Ca^{2+} \text{ influx} →↑ c A MP → PKA activation →↑ L-type C a 2 + influx Cardiac myocytes, SA node, AV node, renal juxtaglomerular (JG) cells Positive chronotropy (increased HR); positive inotropy (increased contractility); positive dromotropy (increased AV conduction velocity); renin release (activates RAAS)
β 2 \beta_2 β 2 G s G_s G s Stimulates adenylyl cyclase → ↑ c A M P → PKA activation → MLCK phosphorylation (inactivation) \rightarrow \uparrow cAMP \rightarrow \text{PKA activation} \rightarrow \text{MLCK phosphorylation (inactivation)} →↑ c A MP → PKA activation → MLCK phosphorylation (inactivation) Bronchial smooth muscle, skeletal muscle arterioles, liver, uterus, skeletal muscle Bronchodilation ; vasodilation in skeletal muscle beds (decreased diastolic BP); hepatic glycogenolysis/gluconeogenesis; cellular K + K^+ K + uptake (stimulates N a + / K + Na^+/K^+ N a + / K + ATPase); tocolysis (uterine relaxation)
β 3 \beta_3 β 3 G s G_s G s Stimulates adenylyl cyclase → ↑ c A M P \rightarrow \uparrow cAMP →↑ c A MP Adipose tissue, urinary bladder detrusor muscle Lipolysis; detrusor muscle relaxation (Mirabegron used for overactive bladder)
- Sympathomimetic Agonists: Clinical Profiles Adrenergic Agonist Hemodynamics
- Agent Primary Receptors Heart Rate (HR) Blood Pressure (MAP)
- ─────────────────────────────────────────────────────────────────────────────
- Epinephrine α1, α2, β1, β2 ↑ (Direct β1) ↑ (High dose) / ↔ (Low)
- Norepinephrine α1 > β1 ↓ (Reflex Bradycardia) ↑↑ (Intense Vasoconstriction)
- Isoproterenol β1 = β2 ↑↑ (Direct β1 + Reflex) ↓ (Profound Vasodilation)
- Phenylephrine Pure α1 ↓↓ (Reflex Bradycardia) ↑↑ (Vasoconstriction)
- Epinephrine (Adrenaline)
Receptor Selectivity: Non-selective agonist; binds α 1 , α 2 , β 1 , β 2 \alpha_1, \alpha_2, \beta_1, \beta_2 α 1 , α 2 , β 1 , β 2 .
Dose-Dependent Hemodynamics:
Low Doses ( 0.01 − 0.05 mcg/kg/min 0.01 - 0.05\text{ mcg/kg/min} 0.01 − 0.05 mcg/kg/min ): Selective for β 1 \beta_1 β 1 and β 2 \beta_2 β 2 receptors. Increases heart rate and stroke volume ( β 1 \beta_1 β 1 ), while dilating skeletal muscle vascular beds ( β 2 \beta_2 β 2 ). Systolic blood pressure rises while diastolic pressure decreases, resulting in widened pulse pressure with little change in mean arterial pressure (MAP).
High Doses ( > 0.1 mcg/kg/min > 0.1\text{ mcg/kg/min} > 0.1 mcg/kg/min ): α 1 \alpha_1 α 1 vasoconstrictor actions dominate over β 2 \beta_2 β 2 vasodilation, resulting in marked systemic vasoconstriction, elevated SVR, and elevated systolic and diastolic blood pressure.
Clinical Indications:
Anaphylactic Shock: First-line emergency drug ( 0.3 − 0.5 mg 0.3 - 0.5\text{ mg} 0.3 − 0.5 mg IM in anterolateral thigh). Reverses life-threatening laryngeal edema and hypotension ( α 1 \alpha_1 α 1 ), reverses bronchospasm and inhibits mast cell degranulation ( β 2 \beta_2 β 2 ), and supports cardiac contractility and output ( β 1 \beta_1 β 1 ).
Cardiopulmonary Resuscitation (ACLS): 1 mg 1\text{ mg} 1 mg IV every 3–5 minutes during cardiac arrest.
Local Anesthetic Additive in Podiatric Surgery: Added at concentrations of 1 : 100 , 000 1:100,000 1 : 100 , 000 or 1 : 200 , 000 1:200,000 1 : 200 , 000 to lidocaine or bupivacaine.
Important
Epinephrine in Podiatric Local Anesthesia: Co-administration of epinephrine with local anesthetics induces localized α 1 \alpha_1 α 1 -mediated arteriolar vasoconstriction. This yields four major clinical benefits:
Prolongs Duration of Blockade: Decreases local vascular absorption, keeping the anesthetic concentrated at the target nerve sheath.
Reduces Peak Systemic Toxicity: Slows systemic absorption, decreasing peak plasma concentrations and reducing risks of Local Anesthetic Systemic Toxicity (LAST).
Provides Operative Hemostasis: Constricts local dermal and subcutaneous microvessels, creating a dry surgical field.
Increases Maximum Allowable Safe Dose: Allows higher total milligrams of anesthetic to be administered safely (e.g., plain lidocaine safe limit is 4.5 mg/kg 4.5\text{ mg/kg} 4.5 mg/kg up to 300 mg 300\text{ mg} 300 mg ; lidocaine with epinephrine safe limit rises to 7.0 mg/kg 7.0\text{ mg/kg} 7.0 mg/kg up to 500 mg 500\text{ mg} 500 mg ).
Digital Anesthesia Historical Caveat & Modern Clinical Judgment: Traditional teaching strictly forbade epinephrine in "fingers, toes, penis, and nose" due to fears of ischemic digital necrosis. Modern large-scale clinical trials have demonstrated that low-dose epinephrine ( 1 : 200 , 000 1:200,000 1 : 200 , 000 ) in digital blocks is safe in healthy patients. However, on national board examinations and in high-risk clinical practice, epinephrine is strictly avoided in digital nerve blocks in patients with severe Peripheral Artery Disease (PAD), Raynaud disease, small-vessel vasculitis, thromboangiitis obliterans (Buerger disease), or heavily compromised end-arterial digital microcirculation .
Norepinephrine (Noradrenaline)
Receptor Selectivity: Potent α 1 > α 2 > β 1 \alpha_1 > \alpha_2 > \beta_1 α 1 > α 2 > β 1 agonist; negligible affinity for β 2 \beta_2 β 2 .
Hemodynamic Profile: Induces intense systemic vasoconstriction in all vascular beds, markedly increasing Systemic Vascular Resistance (SVR), systolic BP, and diastolic BP. Although norepinephrine directly stimulates cardiac β 1 \beta_1 β 1 receptors, the rapid surge in mean arterial pressure activates high-pressure carotid sinus and aortic arch baroreceptors. The resulting compensatory vagal parasympathetic discharge overrides direct β 1 \beta_1 β 1 chronotropic effects, producing Reflex Bradycardia accompanied by high stroke volume.
Clinical Use: First-line vasopressor of choice for septic shock and refractory vasodilatory shock.
Other Clinically Significant Sympathomimetics
Dopamine: Exerts dose-dependent receptor activation:
Low dose ( 1 − 2 mcg/kg/min 1 - 2\text{ mcg/kg/min} 1 − 2 mcg/kg/min ): Binds vascular D 1 D_1 D 1 receptors in renal, mesenteric, and coronary beds, stimulating adenylyl cyclase to promote renal vasodilation.
Intermediate dose ( 2 − 10 mcg/kg/min 2 - 10\text{ mcg/kg/min} 2 − 10 mcg/kg/min ): Stimulates cardiac β 1 \beta_1 β 1 receptors, increasing inotropy and cardiac output.
High dose ( > 10 mcg/kg/min > 10\text{ mcg/kg/min} > 10 mcg/kg/min ): Stimulates vascular α 1 \alpha_1 α 1 receptors, causing generalized vasoconstriction and elevating blood pressure.
Dobutamine: Selective β 1 > β 2 > α 1 \beta_1 > \beta_2 > \alpha_1 β 1 > β 2 > α 1 agonist. Potent inotrope that increases cardiac contractility and stroke volume with minimal chronotropic effect; produces mild β 2 \beta_2 β 2 vasodilation that reduces afterload. Used in cardiogenic shock and pharmacological cardiac stress testing.
Phenylephrine: Pure selective α 1 \alpha_1 α 1 agonist (zero beta activity). Produces profound vasoconstriction, sharp increase in SVR and BP, and dramatic reflex bradycardia. Used as a topical nasal decongestant, mydriatic, and intravenous vasopressor for hypotension during spinal/general anesthesia.
Isoproterenol: Non-selective β 1 = β 2 \beta_1 = \beta_2 β 1 = β 2 agonist (zero alpha activity). Stimulates cardiac β 1 \beta_1 β 1 (profound tachycardia and increased contractility) while stimulating vascular β 2 \beta_2 β 2 (intense skeletal muscle vasodilation, dropping diastolic BP and SVR). MAP falls, triggering additional reflex tachycardia.
Central α 2 \alpha_2 α 2 Agonists (Clonidine & Methyldopa):
Clonidine: Stimulates central presynaptic α 2 \alpha_2 α 2 receptors in the rostral ventrolateral medulla and nucleus tractus solitarius, reducing sympathetic outflow to the heart and vascular tree, lowering blood pressure and heart rate. Rebound Hypertensive Crisis: Abrupt cessation of chronic clonidine triggers a massive surge of catecholamines acting on up-regulated postsynaptic receptors, causing severe rebound hypertension, tachycardia, and stroke. Clonidine must always be tapered gradually.
Methyldopa: Converted in the brain to α \alpha α -methylnorepinephrine, activating central α 2 \alpha_2 α 2 receptors. First-line antihypertensive in pregnancy (safe for fetus). Adverse effect: Direct Coombs-positive autoimmune hemolytic anemia.
Short- and Long-Acting β 2 \beta_2 β 2 Agonists (Albuterol, Salmeterol): Relax bronchial smooth muscle in asthma and COPD. Adverse effects: fine skeletal muscle tremor ( β 2 \beta_2 β 2 mediated), reflex tachycardia, and transient hypokalemia ( β 2 \beta_2 β 2 stimulates N a + / K + Na^+/K^+ N a + / K + ATPase, driving potassium into skeletal muscle cells; utilized therapeutically for emergency hyperkalemia management).
- Sympatholytic Agents: Alpha & Beta Adrenergic Antagonists
- Alpha-Adrenergic Receptor Blockers
Classification Representative Agents Mechanism & Duration Clinical Indications & Adverse Effects
Non-Selective α \alpha α -Blockers Phenoxybenzamine Irreversible, non-competitive covalent blocker of α 1 \alpha_1 α 1 and α 2 \alpha_2 α 2 Preoperative medical management of pheochromocytoma ; prevents intraoperative hypertensive crisis during tumor manipulation. Adverse effects: severe orthostatic hypotension, reflex tachycardia.
Non-Selective α \alpha α -Blockers Phentolamine Reversible, competitive blocker of α 1 \alpha_1 α 1 and α 2 \alpha_2 α 2 Diagnosis of pheochromocytoma; treatment of severe hypertensive crisis from MAOI-tyramine interactions or cocaine; extravasation reversal of IV vasopressors (e.g., norepinephrine) to prevent dermal necrosis.
Selective α 1 \alpha_1 α 1 Blockers Prazosin, Terazosin, Doxazosin Selective competitive blockers of vascular α 1 \alpha_1 α 1 receptors Treatment of systemic hypertension and benign prostatic hyperplasia (BPH). Adverse effect: First-dose syncope and severe orthostatic hypotension ; must be taken at bedtime.
Selective α 1 A \alpha_{1A} α 1 A Blockers Tamsulosin, Silodosin Selective blocker of α 1 A \alpha_{1A} α 1 A receptors concentrated in prostatic smooth muscle and bladder neck First-line pharmacotherapy for Benign Prostatic Hyperplasia (BPH) ; relaxes prostate with minimal vascular α 1 B \alpha_{1B} α 1 B blockade, significantly reducing orthostatic hypotension.
Note
Epinephrine Reversal Phenomenon: Administration of epinephrine alone causes an initial sharp rise in blood pressure due to α 1 \alpha_1 α 1 vasoconstriction overcoming β 2 \beta_2 β 2 vasodilation. However, if epinephrine is administered after pretreatment with a non-selective α \alpha α -blocker (e.g., phentolamine or phenoxybenzamine) , the α 1 \alpha_1 α 1 vasoconstrictor response is completely blocked. Epinephrine's β 2 \beta_2 β 2 agonist action remains unopposed, producing a paradoxical fall in mean arterial blood pressure (vasodilation) . This classic pharmacological response is known as Dale's Epinephrine Reversal .
Loading diagram... Epinephrine Blood Pressure Response Alone vs. Following Alpha-Blockade (Epinephrine Reversal)
Beta-Adrenergic Receptor Blockers
Beta-blockers competitive antagonize catecholamine binding at β 1 \beta_1 β 1 and β 2 \beta_2 β 2 receptors.
Pharmacologic Classification of Beta-Blockers
Class Generic Names Receptor Selectivity Clinical Advantages & Board High-Yield Pearls
Non-Selective (1st Gen) Propranolol, Timolol, Nadolol β 1 = β 2 \beta_1 = \beta_2 β 1 = β 2 Propranolol: Lipophilic, crosses BBB (migraine prophylaxis, essential tremor, thyroid storm); Timolol: topical drops for glaucoma; Nadolol: longest half-life, esophageal varices prophylaxis.
Cardioselective (2nd Gen) Metoprolol, Atenolol, Esmolol, Bisoprolol β 1 > β 2 \beta_1 > \beta_2 β 1 > β 2 (Cardioselective at standard doses) Metoprolol: reduces mortality in post-MI and HFrEF; Esmolol : ultra-short acting ( t 1 / 2 ≈ 9 min t_{1/2} \approx 9\text{ min} t 1/2 ≈ 9 min ), rapidly hydrolyzed by RBC esterases, used for acute intraoperative tachycardia/hypertension.
Combined α 1 / β \alpha_1 / \beta α 1 / β (3rd Gen) Carvedilol, Labetalol β 1 = β 2 \beta_1 = \beta_2 β 1 = β 2 plus α 1 \alpha_1 α 1 blockade Carvedilol: antioxidant properties, reduces mortality in chronic systolic heart failure (HFrEF); Labetalol : first-line IV drug for hypertensive emergencies, acute aortic dissection, and preeclampsia.
Vasodilatory β 1 \beta_1 β 1 (3rd Gen) Nebivolol Highly β 1 \beta_1 β 1 -selective Stimulates endothelial Nitric Oxide (NO) synthase , inducing vasodilation with minimal erectile dysfunction.
Partial Agonists (ISA) Pindolol, Acebutolol Intrinsic Sympathomimetic Activity (ISA) Act as partial agonists; stimulate receptor weakly while blocking stronger endogenous catecholamines. Contraindicated in angina and post-MI because they do not reliably decrease resting heart rate.
Podiatric & Systemic Adverse Consequences
Cardiovascular: Sinus bradycardia, AV conduction block (contraindicated in 2nd/3rd degree AV block), acute exacerbation of decompensated heart failure.
Pulmonary Bronchoconstriction: Blockade of bronchial β 2 \beta_2 β 2 receptors prevents smooth muscle relaxation. In patients with asthma or severe COPD, non-selective beta-blockers can precipitate lethal status asthmaticus . When a beta-blocker is mandatory in a patient with reactive airway disease, a cardioselective β 1 \beta_1 β 1 blocker (e.g., metoprolol or bisoprolol) must be selected with extreme caution.
Peripheral Vascular Exacerbations in Podiatry: In patients with severe Peripheral Artery Disease (PAD) or Raynaud Phenomenon , non-selective beta-blockade eliminates physiological β 2 \beta_2 β 2 -mediated skeletal muscle vasodilation. This leaves systemic vascular α 1 \alpha_1 α 1 receptors unopposed, precipitating severe peripheral digital vasoconstriction, cold extremities, ischemic digital pain, and delayed surgical wound healing.
Masking of Hypoglycemia in Diabetics: Hypoglycemia triggers a compensatory surge of epinephrine that stimulates β 1 \beta_1 β 1 and β 2 \beta_2 β 2 receptors, warning the patient through diaphoresis, tachycardia, palpitations, tremors, and anxiety. Beta-blockers blunt the warning signs of tachycardia and tremor , allowing severe neuroglycopenic hypoglycemia to progress undetected into seizures or coma. Notably, diaphoresis (sweating) is mediated by sympathetic cholinergic M 3 M_3 M 3 receptors and is NOT blocked by beta-blockers, remaining the sole reliable warning sign of hypoglycemia!
Beta-Blocker Overdose & Glucagon Rescue
Beta-blocker toxicity presents with profound sinus bradycardia, hypotension, AV block, cardiogenic shock, and central nervous system depression.
Treatment:
Initial IV atropine and isotonic fluids (frequently ineffective in massive overdose).
Definitive Pharmacologic Antidote: Intravenous Glucagon.
Mechanism of Glucagon: Glucagon binds to independent G-protein-coupled glucagon receptors on cardiac myocyte membranes that couple to G s G_s G s . This bypasses the blocked β \beta β -adrenergic receptors entirely , stimulating adenylyl cyclase to elevate intracellular cyclic AMP ( c A M P cAMP c A MP ). Increased cAMP activates PKA, enhancing intracellular calcium influx to restore myocardial contractility (positive inotropy) and heart rate (positive chronotropy).